IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report
Open Access
- 14 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1370972
Abstract
A 73-year-old man with lung squamous cell carcinoma was administered carboplatin + nab-paclitaxel + pembrolizumab for four cycles. Subsequently, he presented with multiple purpuras on his extremities, joint swelling on his fingers, abdominal pain, and diarrhea, accompanied by acute kidney injury (AKI), increased proteinuria, hematuria, and elevated C-reactive protein levels. Skin biopsy showed leukocytoclastic vasculitis as well as IgA and C3 deposition in the vessel walls. Based on these findings, the patient was diagnosed with IgA vasculitis as an immune-related adverse event (irAE) induced by carboplatin + nab-paclitaxel + pembrolizumab. After discontinuation of pembrolizumab and glucocorticoids, the symptoms immediately resolved. Regular monitoring of skin, blood tests, and urinalysis are necessary, and the possibility of irAE IgA vasculitis should be considered in cases of purpura and AKI during treatment with immune checkpoint inhibitors.Keywords
This publication has 15 references indexed in Scilit:
- IgA vasculitis as an immune-related adverse event of durvalumab: A case reportRespiratory Investigation, 2023
- Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitisScientific Reports, 2021
- A case of Schönlein–Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanomaEuropean Journal of Cancer, 2020
- Checkpoint inhibitor-related renal vasculitis and use of rituximabJournal for ImmunoTherapy of Cancer, 2020
- Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJournal for ImmunoTherapy of Cancer, 2020
- Management of rheumatic complications of ICI therapy: a rheumatology viewpointRheumatology, 2019
- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in CancerDrug Safety, 2019
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Vasculitis associated with immune checkpoint inhibitors—a systematic reviewClinical Rheumatology, 2018
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case ReportsPLOS ONE, 2016